C. Gisselbrecht

发表

[Non-Hodgkin lymphoma arising in a case of Waldmann's intestinal lymphangiectasis].

P. Hérait, C. Gisselbrecht, C. Fermé, 1985, Nouvelle revue francaise d'hematologie.

p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas.

P. Gaulard, G. Salles, F. Berger, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

A predictive model for aggressive non-Hodgkin's lymphoma.

Emili Montserrat, Christian Gisselbrecht, Carlo Tondini, 1993, The New England journal of medicine.

Autologous bone marrow transplantation in Hodgkin's disease.

C. Gisselbrecht, M. Boiron, É. Lepage, 1990, Nouvelle revue francaise d'hematologie.

Prognostic significance of survivin expression in diffuse large B-cell lymphomas.

J Diebold, T. Molina, P. Gaulard, 2000, Blood.

Diversity in antibody-based approaches to non-Hodgkin lymphoma

A. Hagenbeek, D. Maloney, C. Gisselbrecht, 2010, Leukemia & lymphoma.

R-CHOP14 Compared to R-CHOP21 in Elderly Patients with Diffuse Large B-Cell Lymphoma: Results of the Interim Analysis of the LNH03-6B GELA Study

T. Molina, G. Salles, H. Tilly, 2009 .

nine cases and review of the literature

C. Gisselbrecht, C. Fermé, J. Trédaniel, 2002 .

Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: results of a prospective clinical trial with 70 stage IIIB-IV patients.

C. Gisselbrecht, C. Fermé, M. Marty, 1993, International journal of radiation oncology, biology, physics.

Interleukin-2 treatment in lymphoma: a phase II multicenter study.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1994, Blood.

Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms.

J. Blay, C. Gisselbrecht, M. Raphael, 1994, Blood.

Approaches for First-Line Therapy of Peripheral T-Cell Lymphoma

C. Gisselbrecht, D. Sibon, F. Foss, 2013 .

Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives).

F. Berger, B. Coiffier, J. Diebold, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of high-dose chemotherapy on peripheral T-cell lymphomas.

P. Gaulard, C. Gisselbrecht, N. Mounier, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

J. Cerhan, C. Gisselbrecht, E. W. Van Den Neste, 2017, Blood.

The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.

C. Gisselbrecht, E. Laane, R. Hemmings, 2015, The oncologist.

Dose intensive therapy in breast cancer.

C. Gisselbrecht, P. Ljungman, D. Niederwieser, 1992, Bone marrow transplantation.

The impact of pre‐ and post‐transplantation positron emission tomography using 18‐fluorodeoxyglucose on poor‐prognosis lymphoma patients undergoing autologous stem cell transplantation

C. Gisselbrecht, J. Larghero, N. Mounier, 2007, Cancer.

Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients.

C. Gisselbrecht, T. Kishimoto, J. Van Damme, 1992, Blood.

Peripheral T-cell lymphoma

C. Gisselbrecht, D. Sibon, 2013 .

Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma.

B. Coiffier, H. Tilly, C. Gisselbrecht, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor- risk BDLC NHL patients treated with up-front consolidative autotransplantation: A GELA phase II trial (LNH 2003-3).

B. Coiffier, O. Casasnovas, P. Feugier, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.

J. Gribben, F. Cavalli, T. Habermann, 2022, The Lancet. Haematology.

ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia.

J. Soulier, C. Gisselbrecht, N. Mounier, 2008, Clinical advances in hematology & oncology : H&O.

Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective

C. Gisselbrecht, P. Zinzani, M. André, 2020, BMC cancer.

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia

C. Gisselbrecht, F. Pignatti, E. Bałkowiec-Iskra, 2021, HemaSphere.

Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma.

C. Gisselbrecht, N. Mounier, I. Madelaine, 2010, Clinical lymphoma, myeloma & leukemia.

Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins’s disease or non-Hodgkin’s lymphoma

C. Gisselbrecht, C. Fermé, C. Hennequin, 1999, Bone Marrow Transplantation.

5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer.

C. Gisselbrecht, M. Boiron, P. Woolley, 1980, Annals of internal medicine.

Radiation-induced lung injuries: a survey by computed tomography and pulmonary function tests in 18 cases of Hodgkin's disease.

M. Laval-jeantet, C. Gisselbrecht, L. Baud, 1988, European journal of radiology.

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy

C. Gisselbrecht, C. Suh, A. Goy, 2010 .

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

E. Giné, M. Czuczman, J. Winter, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study.

N. Schmitz, C. Gisselbrecht, N. Mounier, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

10 Years Follow-up of the GELA LNH98.5 Study, First Randomized Study Comparing R-CHOP to CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma.

G. Salles, B. Coiffier, R. Bouabdallah, 2009 .

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

D. Miklos, C. Gisselbrecht, C. Jacobson, 2021, Blood advances.

High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.

M. Federico, C. Gisselbrecht, A. Nagler, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long-term results

P. Feugier, M. Federico, C. Gisselbrecht, 2009, Haematologica.

How to define intermediate stage in Hodgkin's lymphoma?

C. Gisselbrecht, C. Sebban, N. Mounier, 2005, European journal of haematology. Supplementum.

High-Dose T herapy a nd A utologous S tem-Cell T ransplantation Versus C onventional T herapy f or P atients W ith A dvanced Hodgkin's L ymphoma R esponding t o F ront-Line T herapy

M. Federico, C. Gisselbrecht, A. Nagler, 2003 .

Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients

D. Gossot, C. Gisselbrecht, V. Meignin, 2000, Medical oncology.

Prognostic factors in advanced Hodgkin's disease: problems and pitfalls. Towards an international prognostic index.

C. Gisselbrecht, C. Fermé, 1995, Leukemia & lymphoma.

Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study.

M. Federico, C. Gisselbrecht, S. Horwitz, 2020, Clinical lymphoma, myeloma & leukemia.

The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study

R. Advani, Sonali M. Smith, A. Tulpule, 2019, Cancer.

Bridging to Transplant in Diffuse Large B Cell Lymphoma

C. Gisselbrecht, E. Neste, E. Van Den Neste, 2016, EMJ Hematology.

High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.

M. Pfreundschuh, C. Gisselbrecht, C. Crawley, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary.

P. Conti, C. Gisselbrecht, A. Bischof Delaloye, 2009, The oncologist.

Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria.

C. Copie-Bergman, A. Rahmouni, C. Gisselbrecht, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients.

P. Gaulard, B. Coiffier, H. Tilly, 2003, Blood.

High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis.

G. Schwarzer, C. Gisselbrecht, H. Kluin-Nelemans, 2007, Cancer treatment reviews.

Modern management of non‐Hodgkin lymphoma in HIV‐infected patients

C. Gisselbrecht, N. Mounier, M. Spina, 2007, British journal of haematology.

Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy

B. Coiffier, É. Oksenhendler, C. Gisselbrecht, 1993 .

The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.

C. Gisselbrecht, D. Hovgaard, F. Pignatti, 2019, The oncologist.

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

G. Brittinger, D. Huhn, U. Jaeger, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.

N. Schmitz, G. Salles, J. Radford, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second-line treatment paradigms for diffuse large B-cell lymphomas

C. Gisselbrecht, C. Thieblemont, 2009, Current oncology reports.

Use of rituximab in diffuse large B‐cell lymphoma in the salvage setting

C. Gisselbrecht, 2008, British journal of haematology.

Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous hematopoietic stem cell transplantation in intermediate and high grade non-Hodgkin's lymphoma: a review.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Advances in the understanding and management of angioimmunoblastic T‐cell lymphoma

P. Gaulard, C. Gisselbrecht, L. de Leval, 2010, British journal of haematology.

Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation.

C. Gisselbrecht, D. Blaise, A. Goldstone, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An update on90Y-ibritumomab tiuxetan in autologous stem cell transplantation

C. Gisselbrecht, 2009 .

All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

A. Stamatoullas, F. Morschhauser, P. Feugier, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Myelodysplasia after autotransplantation.

C. Gisselbrecht, N. Mounier, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas

T. Molina, C. Gisselbrecht, N. Mounier, 1998, Leukemia.

Autologous stem cell transplantation in aggressive non-Hodgkin's lymphoma.

C. Gisselbrecht, 1996, Hematology and cell therapy.

Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Groupe d'Etudes des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma.

C. Gisselbrecht, N. Mounier, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical and immunological study of non‐Hodgkin T‐cell lymphomas (cutaneous and lymphoblastic lymphomas excluded)

C. Gisselbrecht, G. Flandrin, J. Brouet, 1984, British journal of haematology.

Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.

P. Gaulard, B. Coiffier, H. Tilly, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study

B. Quesnel, C. Gisselbrecht, N. Brousse, 2000, Bone Marrow Transplantation.

Autologous Transplantation in Relapsed or Refractory Hodgkin’s Lymphoma – The Challenges

C. Gisselbrecht, 2015 .

Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d'Etude des Lymphomes Agressifs.

G. Salles, F. Berger, B. Coiffier, 1991, The American journal of medicine.

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma

J. Bergh, C. Gisselbrecht, J. Sjöberg, 2017, The oncologist.

The European Medicines Agency Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma

J. Bergh, C. Gisselbrecht, J. Sjöberg, 2017 .

Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more.

F. Cavalli, C. Gisselbrecht, U. Schlegel, 2009, Seminars in oncology.

Quality of life following treatment for B-cell lymphoma

C. Gisselbrecht, N. Mounier, N. Martis, 2011, Expert review of pharmacoeconomics & outcomes research.

Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms.

J. Blay, C. Gisselbrecht, M. Raphael, 1994, Blood.

Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin’s disease: retrospective analysis of 158 cases from the French registry

R. Bouabdallah, O. Casasnovas, C. Gisselbrecht, 1998, Bone Marrow Transplantation.

The EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.

C. Gisselbrecht, F. Pignatti, C. Prieto, 2020, The oncologist.

Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.

C. Gisselbrecht, P. Borchmann, J. Harousseau, 2003, Haematologica.

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry

R. Advani, Sonali M. Smith, A. Tulpule, 2019, Acta Haematologica.

Second-line therapy for lymphoid neoplasms

C. Gisselbrecht, N. Mounier, 2010 .

Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin's disease.

C. Gisselbrecht, M. Boiron, J. Trédaniel, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma.

P. Gaulard, B. Coiffier, H. Tilly, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Hematologic recovery and survival of lymphoma patients after autologous stem-cell transplantation: comparison of bone marrow and peripheral blood progenitor cells.

H. Dombret, C. Gisselbrecht, D. Cazals, 1996, Leukemia & lymphoma.

Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study

N. Schmitz, S. Montoto, T. A. Lister, 2007, Leukemia.

Estimating late adverse events using competing risks after autologous stem‐cell transplantation in aggressive non‐Hodgkin lymphoma patients

C. Gisselbrecht, J. Larghero, N. Mounier, 2005, Cancer.

High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma

C. Gisselbrecht, C. Lebbé, L. Dubertret, 2004, Bone Marrow Transplantation.

Improving Second-Line Therapy in Aggressive Non-Hodgkin's Lymphoma.

C. Gisselbrecht, N. Mounier, 2004, Seminars in oncology.

T-Cell/Histiocyt e-Rich L arge B -Cell L ymphomas a nd C lassical Diffuse L arge B -Cell L ymphomas H ave S imilar O utcome A fter Chemotherapy: A M atched-Control A nalysis

T. Molina, P. Gaulard, R. Bouabdallah, 2003 .

High-dose therapy for indolent lymphoma.

C. Gisselbrecht, N. Mounier, G. Socié, 2002, Critical reviews in oncology/hematology.

The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.

J. Bergh, C. Gisselbrecht, I. Buajordet, 2019, The oncologist.

Factors affecting hematopoietic recovery after autologous peripheral blood progenitor-cell transplantation in aggressive non-Hodgkin's lymphoma: a prospective study of 123 patients.

G. Salles, B. Quesnel, C. Gisselbrecht, 2001, The hematology journal : the official journal of the European Haematology Association.

Immune reconstitution after bone-marrow transplantation.

C. Gisselbrecht, P. Brice, C. Franks, 1989, Cancer treatment reviews.

transplantation in aggressive lymphomas Pregnancies after high-dose chemotherapy and autologous stem cell

C. Gisselbrecht, C. Haioun, M. André, 2012 .

Pregnancies after high-dose chemotherapy and autologous stem cell transplantation in aggressive lymphomas.

C. Gisselbrecht, M. André, P. Brice, 2002, Blood.

Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer.

C. Gisselbrecht, É. Lepage, J. Lotz, 1996, Bone marrow transplantation.

[Therapeutic intensification and hematopoietic stem cell autotransplantation in the treatment of solid tumors in adults: principles, realization and application to the treatment of germ cell, trophoblastic, breast, ovarian and small-cell bronchial tumors. 1].

C. Gisselbrecht, F. Pène, J. Lotz, 1995, La Revue de medecine interne.

The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL.

Bingshu E. Chen, N. Schmitz, C. Gisselbrecht, 2020, Blood advances.

The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.

C. Gisselbrecht, J. Sjöberg, E. Laane, 2013, The oncologist.

Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma.

P. Gaulard, B. Coiffier, C. Gisselbrecht, 2006, Haematologica.

Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era

C. Gisselbrecht, N. Mounier, 2011, Current opinion in oncology.

The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.

C. Gisselbrecht, D. Bowen, F. Pignatti, 2016, The oncologist.

Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma.

J. Cayuela, C. Gisselbrecht, Weili Zhao, 2004, Blood.

Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment

M. Pfreundschuh, C. Gisselbrecht, K. van Besien, 2008, Leukemia & lymphoma.

Prognostic Factors and Long Term Outcome of 138 Adults with Systemic Anaplastic Large-Cell Lymphoma: a Retrospective Study by the Groupe d'Etude Des Lymphomes De l'Adulte (GELA)

P. Gaulard, B. Coiffier, H. Tilly, 2010 .

CURRENT AND FUTURE DEVELOPMENTS IN THE TREATMENT OF CD 30 + LYMPHOMAS *

L. Specht, C. Gisselbrecht, 2015 .

Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma

H. Tilly, C. Gisselbrecht, A. Nagler, 2007, Bone Marrow Transplantation.

Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy.

N. Schmitz, C. Gisselbrecht, P. Colombat, 2010 .

Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma.

G. Salles, B. Coiffier, C. Gisselbrecht, 1995, Blood.

Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.

E. Kimby, N. Schmitz, H. Tilly, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of the bcl-2 gene product in follicular lymphoma.

P. Gaulard, J. Diebold, C. Gisselbrecht, 1992, The American journal of pathology.

Title: A Randomized Study of Interferon Alpha-2b Versus no Treatment as Consolidation

A. López-Guillermo, B. Coiffier, H. Holte, 2013 .

A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1998, Cancer.

Anthracyclines in the treatment of acute nonlymphocytic leukemias.

C. Gisselbrecht, M. Marty, M. Boiron, 1981, Cancer treatment reports.

Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: A randomized study from the GELA: LNH RP 93

G. Salles, B. Coiffier, H. Tilly, 1997 .

Secondary acute myeloid leukemia after autologous bone marrow transplantation for malignant lymphomas.

C. Gisselbrecht, P. Morel, P. Brice, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Peripheral T / Nk Cell Lymphoma Clinic and Therapy

P. Gaulard, C. Gisselbrecht, 2004 .

Image-guided core-needle biopsy of peripheral lymph nodes allows the diagnosis of lymphomas

C. Gisselbrecht, N. Mounier, P. Brice, 2007, European Radiology.

Peripheral T cell lymphoma following angioimmunoblastic lymphadenopathy.

C. Gisselbrecht, M. Boiron, G. Flandrin, 1987, Nouvelle revue francaise d'hematologie.

R-CHOP Versus R-FC Followed by Maintenance with Rituximab Versus Interferon-Alfa: Outcome of the First Randomized Trial for Elderly Patients with Mantle Cell Lymphoma

W. Klapper, E. Hoster, B. Coiffier, 2011 .

Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.

J. Bergh, C. Gisselbrecht, D. Melchiorri, 2020, The oncologist.

Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.

J. Bergh, C. Gisselbrecht, D. Melchiorri, 2019, The oncologist.

Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach.

C. Gisselbrecht, P. Woolley, P. Schein, 1986, Cancer treatment reports.

Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation

W. Siegert, C. Gisselbrecht, P. Biron, 1994, The Lancet.

Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma (NHL) with the ACVBP regimen. A GELA (Groupe d'Etude des Lymphomes de l'Adulte) cohort study on 2849 patients.

P. Gaulard, B. Coiffier, H. Tilly, 2001 .

Effect of Lenograstim on the Cost of Autologous Bone Marrow Transplantation

C. Gisselbrecht, P. Brice, P. Faure, 1995, PharmacoEconomics.

Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.

H. Dombret, A. Baruchel, C. Gisselbrecht, 1992, Bone marrow transplantation.

European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis

C. Gisselbrecht, C. Herberts, F. Pignatti, 2019, ESMO Open.

In vivo purging and relapse prevention following ASCT

C. Gisselbrecht, 2002, Bone Marrow Transplantation.

An unmet need for long-term follow-up in Hodgkin's lymphoma?

C. Gisselbrecht, 2018, The Lancet. Haematology.

Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies

C. Gisselbrecht, P. Morel, P. Rousselot, 2000, Bone Marrow Transplantation.

Chemotherapy of carcinomas of the digestive tract.

C. Gisselbrecht, M. Marty, M. Boiron, 1982, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Results of three courses of adriamycin, bleomycin, vindesine, and dacarbazine with subtotal nodal irradiation in 189 patients with nodal Hodgkin's disease (stage I, II and IIIA).

C. Gisselbrecht, É. Lepage, M. André, 1997, Hematology and cell therapy.

Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response.

J. Vose, A. Nademanee, C. Gisselbrecht, 2009, The Oncologist.

Clinical trials with diglycoaldehyde (NSC-118994): review and reasons for withdrawal from clinical trial.

C. Gisselbrecht, M. Marty, M. Boiron, 1981, Anticancer research.

LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas.

M. Espié, C. Gisselbrecht, P. Rousselot, 2003, The hematology journal : the official journal of the European Haematology Association.

Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring.

B. Coiffier, C. Gisselbrecht, F. Chauvin, 1993, British Journal of Cancer.

A prospective cohort study of patients with peripheral T‐cell lymphoma in the United States

R. Advani, Sonali M. Smith, A. Tulpule, 2017, Cancer.

Biomarker Quality Assurance (QA) Findings From the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry

M. Federico, C. Gisselbrecht, S. Horwitz, 2012 .

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

C. Gisselbrecht, D. Hovgaard, F. Pignatti, 2021, HemaSphere.

Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.

C. Gisselbrecht, Y. Humblet, C. Doyen, 1992, Experimental hematology.

Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.

J. Armitage, J. Vose, B. Coiffier, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

N. Schmitz, C. Gisselbrecht, N. Mounier, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Futility of relapsed diffuse large B cell lymphoma transplantation?

C. Gisselbrecht, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Should we replace dexamethasone, cytarabine, and cisplatin for relapsed lymphoma?

C. Gisselbrecht, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Cancer of the breast: intensive treatment with bone marrow autografts].

M. Espié, C. Gisselbrecht, M. Marty, 1989, Bulletin du cancer.

Immunophenotypic and genotypic analysis of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Correlation with histologic features in 36 cases. French Study Group of Pathology for HIV-Associated Tumors.

K. Lennert, J. Diebold, C. Gisselbrecht, 1994, American journal of clinical pathology.

Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis

B. Coiffier, C. Gisselbrecht, M. Crump, 2015, Experimental Hematology & Oncology.

The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use.

C. Gisselbrecht, E. Laane, F. Pignatti, 2014, The oncologist.

Is Dose-Dense Therapy Effective Against DLBCL in the Era of Rituximab?

C. Gisselbrecht, 2012, Oncology.

[Monoclonal antibodies in the treatment of lymphoma].

C. Gisselbrecht, N. Mounier, 2002, La Revue du praticien.

In Vitro Effect of Cyclophosphamide Metabolites on Chromosomes of Fanconi Anaemia Patients

R. Berger, C. Gisselbrecht, A. Bernheim, 1980, British journal of haematology.

Early Response Evaluation with 18FDG-PET Scanning, but Not Phenotypic Profile, Are Predictive of Outcome in Diffuse Large B-Cell Lymphoma.

C. Copie-Bergman, P. Gaulard, A. Rahmouni, 2005 .

Effect of combination chemotherapy, duration of methotrexate administration, and Patient's age on methotrexate pharmacokinetics

C. Gisselbrecht, M. Marty, M. Boiron, 2004, Cancer Chemotherapy and Pharmacology.

C. Gisselbrecht, D. Blaise, M. André, 1998, Blood.

Hodgkin's lymphoma: what is next in salvage treatment?

C. Gisselbrecht, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.

C. Gisselbrecht, M. Rybojad, P. Morel, 1995, Archives of dermatology.

Successful interleukin‐2 therapy of advanced cutaneous T‐cell lymphoma

C. Gisselbrecht, M. Rybojad, P. Morel, 1992, The British journal of dermatology.

A Prospective Randomized Study Comparing Dose Intensive Immunochemotherapy with R-ACVBP vs Standard R-CHOP In Younger Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-2B

T. Molina, F. Jardin, B. Coiffier, 2010 .

[Epidermotropic T-cell gamma/delta lymphoma].

C. Gisselbrecht, L. Dubertret, S. Aractingi, 1993, Annales de dermatologie et de venereologie.

[Gallium-67 scintigraphy in malignant lymphoma].

C. Gisselbrecht, C. Bris, P. Brice, 1993, Presse medicale.

PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients).

A. Hagenbeek, B. Coiffier, C. Gisselbrecht, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Ultrastructural lesions of bile ducts in primary biliary cirrhosis. A comparison with the lesions observed in graft versus host disease.

C. Gisselbrecht, C. Degott, G. Feldmann, 1981, Human pathology.

Histological and ultrastructural appearance of the liver during graft-versus-host disease complicating bone marrow transplantation.

C. Gisselbrecht, M. Marty, M. Boiron, 1980, Transplantation.

Antineoplastic agents and the liver.

D. Dhumeaux, C. Gisselbrecht, F. Reyes, 1980, Gastroenterology.

EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma

C. Gisselbrecht, M. Zienowicz, H. Enzmann, 2021 .

[Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the national protocol Pegase 04].

B. Asselain, C. Gisselbrecht, J. Lotz, 1999, Hematology and Cell Therapy.

Phase I study of bisantrene in acute nonlymphoblastic leukemia.

C. Gisselbrecht, M. Marty, M. Boiron, 1985, Cancer treatment reports.

Enrichment of peripheral blood CD34+ cells for transplantation using a fully automated immunomagnetic cell selection system and a novel octapeptide releasing agent

C. Gisselbrecht, J. Lotz, J. Fermand, 1999, Bone Marrow Transplantation.

Cost effectiveness of day 5 G-CSF (Lenograstim®) administration after PBSC transplantation: results of a SFGM-TC randomised trial

J. Bourhis, C. Gisselbrecht, A. Aupérin, 2005, Bone Marrow Transplantation.

Management of Non-Hodgkin’s Lymphomas: Conclusions of the First Intercity Meeting, 1986

B. Coiffier, C. Gisselbrecht, C. Patte, 1990 .

European School of Oncology: management of non-Hodgkin's lymphomas: conclusions of the European School of Oncology Meeting, 1986.

B. Coiffier, C. Gisselbrecht, C. Patte, 1987, European journal of cancer & clinical oncology.

Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.

K. Hoang-Xuan, M. Sanson, O. Casasnovas, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study

A. Rosenwald, N. Schmitz, P. Gaulard, 2010 .

No Role for Chemoradiotherapy When Compared with Chemotherapy Alone in Elderly Patients with Localized Low Risk Aggressive Lymphoma: Final Results of the LNH93-4 GELA Study.

T. Molina, H. Tilly, B. Quesnel, 2005 .

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

J. Gribben, F. Cavalli, T. Habermann, 2018, The Lancet. Haematology.

Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin’s lymphoma

J. Briones, G. Salles, F. Cavalli, 2013, Haematologica.

Antineoplastic agents and the liver

D. Dhumeaux, C. Gisselbrecht, F. Reyes, 1980 .

Mycosis fungoides and the Sézary syndrome.

C. Gisselbrecht, L. Dubertret, 1993, Nouvelle revue francaise d'hematologie.

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

A. Hagenbeek, B. Coiffier, P. Sonneveld, 1995, The New England journal of medicine.

Quantification of urinary allantoin by capillary zone electrophoresis during recombinant urate oxydase (rasburicase) therapy.

C. Gisselbrecht, N. Mounier, P. Houzé, 2006, Clinical biochemistry.

Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).

P. Gaulard, F. Berger, B. Coiffier, 1998, Blood.

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

R. Advani, A. Nademanee, J. Friedberg, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

des Lymphomes de l'Adulte (GELA) trials angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude Clinical, biologic, and pathologic features in 157 patients with

P. Gaulard, B. Coiffier, J. Diebold, 2013 .

Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.

P. Gaulard, B. Coiffier, H. Tilly, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular signatures in T-cell lymphoma.

C. Gisselbrecht, 2010, Blood.

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.

P. Gaulard, B. Coiffier, J. Diebold, 2008, Blood.

Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study.

P. Gaulard, F. Berger, B. Coiffier, 2006, Blood.

Managing large cell lymphoma.

C. Gisselbrecht, N. Mounier, 2006, Annals of Oncology.

Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte.

A. Stamatoullas, F. Morschhauser, P. Feugier, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.

T. Molina, B. Coiffier, H. Tilly, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Shortened Firs t-Line High-Dose Chemotherapy for Pat ients With Poor-Prognosis Aggress ive Lymphoma

T. Molina, B. Coiffier, H. Tilly, 2002 .

Report of the European Task Force on Lymphomas: workshop on peripheral T-cell lymphomas.

P. Gaulard, E. Campo, E. Montserrat, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

A multivariate analysis of the survival of patients with aggressive lymphoma

B. Coiffier, H. Tilly, C. Gisselbrecht, 1998 .

Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.

P. Gaulard, B. Coiffier, H. Tilly, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alternance of chemotherapy does not improve results in aggressive non-Hodgkin's lymphoma: A prospective randomized study on 884 patients LNH87 protocol group 3: A gela study

P. Gaulard, B. Coiffier, H. Tilly, 1996 .

Original article: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen

F. Berger, B. Coiffier, J. Diebold, 1990 .

Failure of phenobarbital to increase bilirubin production in the rat.

C. Gisselbrecht, P. Berk, Christian Gisselbrecht, 1974, Biochemical pharmacology.

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

T. Molina, B. Coiffier, H. Tilly, 2003, Blood.

The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells.

Christian Gisselbrecht, Karen Leroy, Françoise Berger, 2007, Blood.

lymphomas Prognostic significance of survivin expression in diffuse large B-cell

T. Molina, P. Gaulard, G. Salles, 2013 .

Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry

M. Federico, C. Gisselbrecht, S. Horwitz, 2019, American journal of hematology.

EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma.

K. Norga, C. Gisselbrecht, B. Hofner, 2020, The oncologist.

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

N. Schmitz, J. Radford, C. Gisselbrecht, 2017, Bone Marrow Transplantation.

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study

N. Schmitz, G. Salles, J. Radford, 2016, Bone Marrow Transplantation.

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.

E. Hoster, W. Hiddemann, G. Lenz, 2004, Blood.

TREATMENT OF HIV-RELATED NON-HODGKIN'S LYMPHOMA ADAPTED TO PROGNOSTIC FACTORS.

R. Bouabdallah, C. Gisselbrecht, M. Schrappe, 1999 .

Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial.

A. Hagenbeek, P. Sonneveld, C. Gisselbrecht, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.

K. Savage, B. Coiffier, C. Gisselbrecht, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined modality in Hodgkin's disease: Comparison of six versus three courses of MOPP with clinical and surgical restaging

C. Gisselbrecht, M. Boiron, C. Fermé, 1984, Cancer.

Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency.

Martine, S. Hamilton-Dutoit, C. Gisselbrecht, 1993, The American journal of pathology.

Autologous stem cell transplantation in lymphoma.

N. Schmitz, C. Buske, C. Gisselbrecht, 2007, Seminars in hematology.

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

P. Gaulard, F. Berger, B. Coiffier, 2003, Blood.

Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study.

T. Molina, F. Jardin, G. Salles, 2010, Blood.

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

P. Gaulard, G. Salles, B. Coiffier, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

B. Coiffier, A. Berkenblit, C. Gisselbrecht, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia.

C. Gisselbrecht, C. Sebban, É. Lepage, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long term hematologic recovery after autologous stem cell transplantation in lymphoma patients: impact of the number of prefreeze and post-thaw CD34+ cells.

C. Gisselbrecht, J. Larghero, N. Mounier, 2005, Bulletin du cancer.

B. Coiffier, C. Gisselbrecht, N. Mounier, 2006 .

The Treatment of AIDS-Related Lymphoma

É. Oksenhendler, C. Gisselbrecht, S. Monfardini, 1992 .

Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).

C Sebban, B. Coiffier, H. Tilly, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

l'Adulte (GELA) trials first-line polychemotherapy within the Groupe d'Etude des Lymphomes de with NK/T-cell lymphoma : results of a Western series of 48 patients treated Expression of the granzyme B inhibitor PI9 predicts outcome in nasal

F. Berger, C. Gisselbrecht, J. Bosq, 2013 .

Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.

P. Gaulard, F. Berger, C. Gisselbrecht, 2007, Blood.

Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making.

R. Gelber, A. Goldhirsch, C. Gisselbrecht, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries

D. Weisenburger, J. Vose, N. Schmitz, 2003, British journal of haematology.

Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets

T. Molina, P. Gaulard, F. Berger, 2015, Haematologica.

Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is nivolumab an option for Hodgkin's lymphoma?

C. Gisselbrecht, 2016, The Lancet. Oncology.

nine c cases a and r review o of t the l literature

C. Gisselbrecht, J. Trédaniel, P. Brice, 1994 .

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Pierre Morel, Raoul Herbrecht, Felix Reyes, 2002, The New England journal of medicine.

Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.

C. Gisselbrecht, D. Costagliola, M. Raphael, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B‐cell lymphoma

G. Salles, C. Gisselbrecht, N. Mounier, 2009, Cancer.

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.

B. Coiffier, T. Lister, M. Ghielmini, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.

B. Coiffier, T. Lister, M. Ghielmini, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma.

P. Gaulard, P. Brousset, C. Gisselbrecht, 2012, Blood.

Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression

É. Oksenhendler, C. Gisselbrecht, Weili Zhao, 2004, Laboratory Investigation.

standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma Intensive conventional chemotherapy (ACVBP regimen) compared with

T. Molina, B. Coiffier, H. Tilly, 2009 .

CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

T. Molina, H. Tilly, B. Quesnel, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol.

T. Delozier, B. Asselain, C. Gisselbrecht, 2005, European journal of cancer.

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.

P. Gaulard, G. Salles, B. Coiffier, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF.

R. Talamini, C. Gisselbrecht, A. Carbone, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1997, Leukemia & lymphoma.

Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients.

C. Gisselbrecht, É. Lepage, P. Morel, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The significance of a residual mediastinal mass following treatment for aggressive non-Hodgkin's lymphomas.

C. Gisselbrecht, É. Lepage, J. Trédaniel, 1992, The European respiratory journal.

patients at high risk of relapse candidates for intensifica- tion with HDT and ASCT.

C. Gisselbrecht, P. Brice, G. Visani, 2009 .

Possible toxicity with the association of G-CSF and bleomycin

B. Coiffier, C. Gisselbrecht, F. Reyes, 1994, The Lancet.

Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas

P. Gaulard, G. Salles, F. Berger, 2006, Oncogene.

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.

Martin Dreyling, Michael Unterhalt, Wolfgang Hiddemann, 2006, Blood.

Network German Low Grade Lymphoma Study Group ( GLSG ) and the European Mantle Cell Lymphoma

W. Klapper, E. Hoster, W. Hiddemann, 2007 .

Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte.

G. Salles, B. Coiffier, H. Tilly, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.

C. Copie-Bergman, M. Baia, T. Molina, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.

A. Rosenwald, N. Schmitz, P. Gaulard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA

G. Salles, O. Casasnovas, P. Feugier, 2011, Haematologica.

Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis.

N. Schmitz, C. Gisselbrecht, M. Bargetzi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab

T. Molina, P. Gaulard, G. Salles, 2008, Leukemia.

Respective prognostic values of germinal center phenotype and early (18)fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma.

C. Copie-Bergman, P. Gaulard, A. Rahmouni, 2007, Haematologica.

(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.

B. Coiffier, H. Tilly, C. Gisselbrecht, 2011, Clinical lymphoma, myeloma & leukemia.

Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT

J. Vose, S. Montoto, Sonali M. Smith, 2019, JAMA oncology.

Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.

G. Salles, B. Coiffier, M. Ghielmini, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Current approaches to the treatment of non-Hodgkin's lymphoma

C. Gisselbrecht, 2011, Hematology reports.

Decision-making in the management of adult classical Hodgkin's lymphoma: determining the optimal treatment.

C. Gisselbrecht, N. Mounier, 2015, Expert review of hematology.

How I manage patients with relapsed/refractory diffuse large B cell lymphoma

C. Gisselbrecht, E. Van Den Neste, 2018, British journal of haematology.

Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma.

G. Salles, J. Jais, O. Casasnovas, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients.

P. Gaulard, B. Quesnel, C. Gisselbrecht, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term follow-up of high-dose treatment (HDT) with autologous haematopoietic progenitor cell support in 702 patients (pts.) with follicular lymphoma (FL). An EBMT registry study.

N. Schmitz, S. Montoto, A. Rohatiner, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low–intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol

T. Molina, B. Coiffier, H. Tilly, 2010, Leukemia & lymphoma.

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease

C. Gisselbrecht, F. Pignatti, S. Urach, 2021, HemaSphere.

Fluorouracil (F), adriamycin (A), and cisplatin (P) (FAP): Combination chemotherapy of advanced esophageal carcinoma

C. Gisselbrecht, M. Marty, F. Calvo, 1983 .

[Primary rectal malignant melanoma. A case report and review of the literature (author's transl)].

C. Gisselbrecht, J. Ferry, C. Hoang, 1981, Gastroentérologie Clinique et Biologique.

New perspectives in the therapeutic approach of peripheral T-cell lymphoma

C. Gisselbrecht, D. Sibon, 2018, Current opinion in oncology.

Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies

D. Biau, G. Salles, H. Tilly, 2016, Leukemia & lymphoma.

Endobronchial presentation of Hodgkin's disease: a report of nine cases and review of the literature.

C. Gisselbrecht, J. Trédaniel, P. Brice, 1994, The European respiratory journal.

T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis.

T. Molina, P. Gaulard, R. Bouabdallah, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.

C. Gisselbrecht, H. Hagberg, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

The Parma international randomized study in relapsed non Hodgkin lymphoma: 1st interim analysis of 128 patients (as 15 January 1991: 153 patients).

A. Hagenbeek, B. Coiffier, C. Gisselbrecht, 1991, Bone Marrow Transplantation.

Do we have to exclude all relapsed diffuse large B‐cell lymphoma patients not in complete remission from autologous stem cell transplant?

C. Gisselbrecht, D. Sibon, 2022, British Journal of Haematology.

ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).

M. Kersten, N. Schmitz, P. Riedell, 2018 .

Peripheral blood stem cell CD34+ autologous transplant in relapsed follicular lymphoma.

J. Cayuela, C. Gisselbrecht, P. Brice, 1997, Hematology and cell therapy.

Cutaneous type of adult T cell leukemia/lymphoma in a French West Indian woman. Clonal rearrangement of T-cell receptor beta and gamma genes and monoclonal integration of HTLV-I proviral DNA in the skin infiltrate.

F. Sigaux, C. Gisselbrecht, A. Gessain, 1990, Journal of the American Academy of Dermatology.

90Yttrium ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory. follicular lymphoma. GELA phase II study

B. Coiffier, H. Tilly, C. Gisselbrecht, 2007 .

Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma.

C. Gisselbrecht, K. Tobinai, M. Dreyling, 2009, The oncologist.

Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma.

E. Hoster, W. Hiddemann, M. Pfreundschuh, 2009 .

Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).

C Sebban, G. Salles, R. Bouabdallah, 2000, Blood.

Ofatumumab in diffuse large B cell lymphoma?

C. Gisselbrecht, 2013, Blood.

Comment on Matasar et al , page 499 Ofatumumab in diffuse large B cell lymphoma ?

C. Gisselbrecht, 2013 .

Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?

C. Gisselbrecht, 2012, Hematology. American Society of Hematology. Education Program.

Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2.

P. Gaulard, G. Salles, M. Copin, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[Adult T-cell leukemia and non-malignant adenopathies associated with HTLV I virus. Apropos of 17 patients born in the Caribbean region and Africa].

H. Dombret, C. Gisselbrecht, D. Dormont, 1990, Presse medicale.

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma

D. Miklos, C. Gisselbrecht, C. Jacobson, 2019, Blood.

Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate‐dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy

C. Gisselbrecht, C. Sebban, X. Troussard, 1990, Cancer.

Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL)

R. Advani, Sonali M. Smith, A. Tulpule, 2014 .

Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma: Results of the phase II RAIL trial--A prospective study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

P. Gaulard, O. Casasnovas, C. Gisselbrecht, 2010 .

A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma

J. Radford, C. Gisselbrecht, C. Suh, 2015, Leukemia and Lymphoma.

1040 Observational study for iron supplementation during Epoietin alpha biosimilar treatment of chemotherapy-induced anemia in cancer patients in oncology and haematology: The SYNERGY study

C. Gisselbrecht, D. Spaeth, I. Ray-Coquard, 2015 .

Relapses, treatments and new drugs.

C. Gisselbrecht, N. Mounier, 2012, Best practice & research. Clinical haematology.

EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma

C. Gisselbrecht, D. Hovgaard, F. Pignatti, 2018, The oncologist.

Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma

E. Hoster, W. Hiddemann, M. Pfreundschuh, 2008 .

Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: A randomized phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

G. Salles, C. Gisselbrecht, N. Mounier, 2007 .

Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant

B. Coiffier, P. Feugier, H. Tilly, 2011, Leukemia & lymphoma.

Rituximab Combined to ACVBP (R-ACVBP) Supported by Pegfilgrastim as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Results of LNH 03–39B. A GELA Study.

B. Coiffier, J. Jais, O. Casasnovas, 2007 .

Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.

P. Gaulard, B. Coiffier, J. Diebold, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High‐dose therapy and autologous stem‐cell transplantation can improve event‐free survival for indolent lymphoma

L. Quéro, C. Gisselbrecht, N. Mounier, 2007, Cancer.

Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.

G. Salles, R. Bouabdallah, J. Jais, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: Results of the interim analysis of the AATT trial.

A. Rosenwald, M. Ziepert, N. Schmitz, 2017 .

Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.

R. Bouabdallah, H. Tilly, C. Gisselbrecht, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Survival Impact of Rituximab Combined to ACVBP (R-ACVBP) in 209 Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Upfront High-Dose Consolidative Autotransplantation (HDC) : A GELA Phase II Study

B. Coiffier, O. Casasnovas, P. Feugier, 2008 .

Autologous Stem Cell Transplantation in Intermediate and High Grade Lymphoma

B. Coiffier, C. Gisselbrecht, 2020 .

Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.

A. Baruchel, C. Gisselbrecht, M. Boiron, 1991, Nouvelle revue francaise d'hematologie.

Autologous BMT for post-remission therapy in adult ALL: an immunological approach. For The French Group of Therapy of Adult ALL.

C. Gisselbrecht, C. Sebban, X. Troussard, 1994, Leukemia & lymphoma.

The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

J. Bergh, C. Gisselbrecht, E. Laane, 2017, The oncologist.

Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial

C. Copie-Bergman, C. Burton, F. Cavalli, 2009, British journal of haematology.

A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL.

A. Rosenwald, M. Ziepert, N. Schmitz, 2020, Blood.

Groupe d'Etude des Lymphomes de l'Adulte (GELA) patients with advanced-stage Hodgkin lymphoma: a study by the Long-term results and competing risk analysis of the H89 trial in

O. Casasnovas, C. Gisselbrecht, N. Mounier, 2013 .

cell lymphoma A new prognostic index (MIPI) for patients with advanced-stage mantle

W. Klapper, W. Hiddemann, H. Einsele, 2008 .

MYC diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

A. Rosenwald, P. Gaulard, R. Houlgatte, 2012 .

Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses

R. Houlgatte, P. Feugier, C. Gisselbrecht, 2016, Oncotarget.

or R-DHAP followed by BEAM plus autologous stem cell transplantation diffuse large B-cell lymphoma is not salvaged by classical R-ICE + MYC

A. Rosenwald, P. Gaulard, R. Houlgatte, 2012 .

Refining the treatment of follicular lymphoma

W. Wilson, J. Gribben, C. Buske, 2008, Leukemia & lymphoma.

VEGF121, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers.

P. Gaulard, R. Houlgatte, C. Gisselbrecht, 2017, Oncotarget.

Treatment of low‐grade non‐Hodgkin's lymphomas: Assessment of doxorubicin in a controlled trial

B. Coiffier, C. Gisselbrecht, M. Boiron, 1990, Hematological oncology.

Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.

P. Gaulard, C. Gisselbrecht, É. Lepage, 2001, The hematology journal : the official journal of the European Haematology Association.

TP53 mutations and rituximab-CHOP.

C. Gisselbrecht, 2012, Blood.

Rituximab: Enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma.

C. Gisselbrecht, N. Mounier, 2003, Seminars in oncology.

Rituximab vs Observation after High-Dose Consolidative First-Line Chemotherapy (HDC) with Autologous Stem Cell Transplantation in Poor Risk Diffuse Large B-Cell Lymphoma. Final Analysis of the LNH98-B3 GELA Study.

B. Coiffier, P. Feugier, H. Tilly, 2005 .

Can we improve ABVD in Hodgkin's lymphoma?

C. Gisselbrecht, 2013, The Lancet. Oncology.

Comparison o f H igh-Dose T herapy a nd A utologous S tem-Cell Transplantation W ith C onventional T herapy f or H odgkin's Disease I nduction F ailure: A C ase-Control S tudy

B. Coiffier, C. Gisselbrecht, D. Blaise, 1999 .

Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy.

C. Gisselbrecht, P. Brice, E. de Kerviler, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Monarthritis revealing non-Hodgkin's T cell lymphoma of the synovium.

É. Oksenhendler, A. de Roquancourt, C. Gisselbrecht, 1988, Arthritis and rheumatism.

Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.

J. Blay, A. Stamatoullas, B. Quesnel, 2000, Haematologica.

Analysis of Peripheral T‐cell Lymphoma Diagnostic Workup in the United States

R. Advani, Sonali M. Smith, A. Tulpule, 2017, Clinical lymphoma, myeloma & leukemia.

Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

C. Gisselbrecht, S. Horwitz, N. Bartlett, 2010 .

Aggressive non Hodgkin lymphoma in the elderly. A retrospective study of 72 patients with clinical features and treatment.

C. Gisselbrecht, M. Boiron, É. Lepage, 1990, Nouvelle revue francaise d'hematologie.

Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

O. Casasnovas, C. Gisselbrecht, N. Mounier, 2006, Blood.

[Prevention of chemotherapy-induced alopecia in cancer patients by scalp hypothermia (author's transl)].

C. Gisselbrecht, M. Marty, M. Boiron, 1982, La Nouvelle presse medicale.

[Methotrexate-induced skin detachment].

C. Gisselbrecht, L. Dubertret, P. Brice, 1992, Presse medicale.

Chemotherapy dose intensity facilitated by use of lenograstim--implications for quality of life and survival.

C. Gisselbrecht, 1994, European Journal of Cancer.

Improving second-line therapy in aggressive non-Hodgkin's lymphoma.

C. Gisselbrecht, N. Mounier, 2004, Seminars in oncology.

[Aggressive lymphomas].

C. Gisselbrecht, 1993, La Revue du praticien.

Autoimmune hemolytic anemia disclosing Hodgkin's disease associated with Castleman's disease.

C. Gisselbrecht, P. Brice, B. Epardeau, 1991, Nouvelle revue francaise d'hematologie.

Outcomes in Refractory Aggressive Diffuse Large B Cell Lymphoma (DLBCL): Results from the International SCHOLAR-1 Study

J. Cerhan, C. Gisselbrecht, M. Crump, 2016 .

The Gene Expression Profile of Nodal T-Cell Lymphomas Identifies a Molecular Link between Angioimmunoblastic T-Cell Lymphoma (AITL) and Follicular Helper T Cells (TFH), and between CD30+ Peripheral T-Cell Lymphoma and ALK-Negative Anaplastic Large Cell Lymphoma (ALCL).

T. Molina, P. Gaulard, F. Berger, 2006 .

Preliminary Report of a Phase 1 Study of CMC-544, an Antibody-Targeted Chemotherapy Agent, in Patients with B-Cell Non-Hodgkin’s Lymphoma (NHL).

E. Giné, A. Rohatiner, C. Gisselbrecht, 2005 .

European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

J. Bergh, C. Gisselbrecht, D. Melchiorri, 2019, ESMO Open.

Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma.

R. Gascoyne, H. Müller-Hermelink, D. Jong, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with Refractory, Aggressive Non-Hodgkinlymphoma (NHL)

D. Miklos, C. Gisselbrecht, C. Jacobson, 2017 .

A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05-1T trial.

P. Gaulard, B. Coiffier, F. Morschhauser, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disseminated toxoplasmosis following autologous bone marrow transplantation.

C. Gisselbrecht, F. Geissmann, F. Derouin, 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.

C. Gisselbrecht, L. S. Nilssen, F. Pignatti, 2020, The oncologist.

Reducing Bureaucracy in Clinical Research: A Call for Action

J. Gribben, P. Sonneveld, E. Macintyre, 2020, HemaSphere.

Independent Predictive Value of PET-CT Pre Transplant in Relapsed and Refractory Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Included in the CORAL Study.

N. Schmitz, S. Montoto, C. Gisselbrecht, 2009 .

A revival: radioimmunotherapy in mucosa associated lymphoid tissue lymphoma

C. Gisselbrecht, 2011, Leukemia & lymphoma.

Alternating Chemotherapy Does Not Improve Results in Poor-prognosis Aggressive Lymphomas - Lnh87 Protocol Group-3 - a Gela Study

P. Gaulard, B. Coiffier, H. Tilly, 1993 .

The European Medicines Agency Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.

C. Gisselbrecht, F. Pignatti, M. Zienowicz, 2021, The oncologist.

Ifosfamide salvage treatment before autologous stem cell transplantation in patients with refractory and relapsed Hodgkin's lymphoma: a GELA experience.

C. Gisselbrecht, N. Mounier, P. Brice, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Rituximab compared to observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor-risk diffuse large B-cell lymphoma: Updated results of the LNH98-B3 GELA study

B. Coiffier, H. Tilly, C. Gisselbrecht, 2007 .

Rituximab Combined to ACVBP (R-ACVBP) as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Preliminary Results on 119 Patients of a GELA Phase II Study.

B. Coiffier, O. Casasnovas, H. Tilly, 2006 .

EPIRUBICIN, BLEOMYCIN, VINBLASTINE AND PREDNISONE (EBVP) CHEMOTHERAPY(CT) IN COMBINATION WITH ANTIRETOVIRAL THERAPY AND PRIMARY USE OF G-CSF FOR PATIENTS (PTS) WITH HODGKIN'S DISEASE AND HIV INFECTION (HD-HIV).: 63

C. Gisselbrecht, U. Tirelli, E. Vaccher, 1997 .

182 P - Epirubicin, bleomycin, vinblastine and prednisone (EBVP) chemotherapy (CT) in combination with antiretroviral therapy and primary use of G-CSF for patients (pts) with hodgkin's disease and HIV infection (HD-HIV)

A. Levis, C. Gisselbrecht, U. Tirelli, 1996 .

Collection, cryopreservation and autologous transplantation with circulating hemopoietic stem cells in patients with multiple myeloma and lymphoma.

C. Gisselbrecht, J. Fermand, M. Benbunan, 1990, Bone marrow transplantation.

Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.

C. Copie-Bergman, M. Baia, T. Molina, 2012 .

Hodgkin's lymphoma: new treatment ideas for an old disease

C. Gisselbrecht, 2005 .

R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study.

N. Schmitz, P. Gaulard, C. Gisselbrecht, 2007 .

Autologous stem cell transplantation in aggressive non-Hodgkin's lymphoma.

C. Gisselbrecht, 1996, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma.

A. López-Guillermo, B. Coiffier, H. Holte, 2013, The oncologist.

MYC diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

A. Rosenwald, P. Gaulard, R. Houlgatte, 2012 .

Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma.

J. Cayuela, C. Gisselbrecht, Weili Zhao, 2004, Blood.

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Lauren C. Chong, A. Rosenwald, W. Chan, 2018, Blood.

Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.

B. Coiffier, C. Gisselbrecht, N. Brousse, 1993, The New England journal of medicine.

Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes.

L. Xerri, É. Oksenhendler, C. Katlama, 2001, The American journal of medicine.

Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring.

B. Coiffier, C. Gisselbrecht, F. Chauvin, 1993, British Journal of Cancer.

Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.

P. Conti, C. Gisselbrecht, D. Delbeke, 2009, The oncologist.

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma

J. Bergh, C. Gisselbrecht, J. Sjöberg, 2018, The oncologist.

Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group.

B. Coiffier, É. Oksenhendler, C. Gisselbrecht, 1993, The American journal of medicine.

MYC diffuse large B-cell lymphoma is not salvaged by classical RICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

A. Rosenwald, P. Gaulard, R. Houlgatte, 2012 .

Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.

C. Copie-Bergman, M. Baia, T. Molina, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies

D. Biau, G. Salles, H. Tilly, 2016, Leukemia and Lymphoma.

Fluorouracil (F), adriamycin (A), and cisplatin (P) (FAP): Combination chemotherapy of advanced esophageal carcinoma

C. Gisselbrecht, F. Calvo, D. Belpomme, 1983, Cancer.

Cognitive Effects of Once Weekly (QW) Epoetin Alfa in Anemic Patients (pts) with Hematologic Malignancies Receiving Chemotherapy (CT): Interim Results of the EPOLYM Trial.

H. Tesch, G. Avvisati, C. Gisselbrecht, 2004 .

C. Copie-Bergman, C. Gisselbrecht, M. Meignan, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical , biologic , and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d ’ Etude des Lymphomes de l ’ Adulte ( GELA ) trials

P. Gaulard, B. Coiffier, R. Bouabdallah, 2008 .

The European Medicines Agency Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia.

C. Gisselbrecht, F. Pignatti, P. V. van Hennik, 2021, The Oncologist.

large B-cell lymphoma of Waldeyer ’ s ring has distinct clinicopathologic features: a GELA study

C. Copie-Bergman, M. Baia, P. Gaulard, 2012 .

Plitidepsin Is Active in Peripheral T-Cell Lymphoma (PTCL): A Subset Analysis from An Ongoing Multicenter Phase II Trial.

J. Briones, C. Gisselbrecht, E. Zucca, 2008 .

Long term results of the GELA study, R-CHOP vs. CHOP in elderly patients with diffuse large B-cell lymphoma.

G. Salles, R. Bouabdallah, P. Feugier, 2004 .

Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE): First Detailed Report of Primary Treatment

M. Federico, C. Gisselbrecht, S. Horwitz, 2012 .

Safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-Cell lymphoma (DLBCL) treated with R-CHOP 14 or RCHOP21: Preliminary results of the LNH03-6B randomized GELA study.

B. Coiffier, H. Tilly, C. Gisselbrecht, 2006 .

Relapses, treatments and new drugs.

C. Gisselbrecht, N. Mounier, 2012, Best practice & research. Clinical haematology.

Angioimmunoblastic T-Cell Lymphoma: A Clinicopathologic Study of 158 Patients Treated in GELA (Groupe d’ Etude des Lymphomes de l’ Adulte) Trials.

T. Molina, P. Gaulard, J. Diebold, 2006 .

Is Good Clinical Practice Becoming Poor Clinical Care?

A. López-Guillermo, M. Dimopoulos, C. Gisselbrecht, 2017, HemaSphere.